Login / Signup

First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.

Mark YarchoanJohn D PowderlyBruno R BastosThomas Benjamin KarasicOxana V CryslerPamela N MunsterMeredith A McKeanLeisha A EmensYvonne M SaengerYasser GedRobert StaggSteven SmithChan C WhitingAnne MoonPeppi PrasitYonchu JenkinsNathan StandiferThomas W DubenskySam H WhitingSusanna V Ulahannan
Published in: Cancer research communications (2024)
TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.
Keyphrases
  • endothelial cells
  • open label
  • clinical trial
  • study protocol
  • phase ii
  • randomized controlled trial
  • phase iii
  • metabolic syndrome
  • induced pluripotent stem cells
  • young adults
  • fatty acid